Pfizer Vaccines launches first Centre of Excellence

The University of Louisville has been named as Pfizer’s first ‘Centre of Excellence’, part of its Vaccine Division’s global programme of collaborations with academic institutions to conduct real-world research on vaccine-preventable diseases affecting adults.

The University of Louisville (UofL) will initially conduct two separate, large population-based epidemiological studies in adults – a one-year study of the incidence of infectious diarrhoea with funding provided by Pfizer up to $6.5 million, and a one-year study of the incidence of pneumonia with funding provided by Pfizer up to $4.5 million.

“The Centres of Excellence will complete comprehensive, disease surveillance and real-world vaccine effectiveness studies, which are distinctly different from clinical safety and efficacy research,” said Luis Jodar, Chief Medical and Scientific Affairs Officer at Pfizer Vaccines.

“With strategically located research centres around the world, we anticipate being able to better define and understand global disease burden in adults and vaccine effectiveness, which will help provide robust evidence to national policymakers and health officials who develop recommendations for the use of vaccines in immunisation programs worldwide.”

Julio Ramirez, Chief of UofL Infectious Diseases and Centre Director, said: “To develop a vaccine, it is important to understand the overall population burden of disease that the vaccine is going to prevent: How common is this illness? Who are the patients that are at higher risk?

“These are the questions we will be addressing with the types of studies we are going to be doing in Louisville, Kentucky.”

Pfizer Vaccines is currently planning to establish a few additional Centres of Excellence for epidemiological research strategically located around the world in the coming years. A second global centre anticipated in the first half of 2020.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Related news

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...